Letrazole 2.5 - Livewell Pharmaceuticals

Letrozole entered clinical use at a time when estrogen suppression was gaining importance in both oncology and endocrinology. As a highly selective third-generation agent, it improved treatment outcomes for breast cancer patients resistant to earlier therapies. Novartis launched Femara with broad international distribution, securing market presence across dozens of countries. In the years following, bodybuilders and athletes turned to the drug for managing estrogenic side effects from steroids, expanding its reach far beyond its original clinical audience.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrazole 2.5 by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.